600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study – Market Wire
unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. Active Biotech is obligated to publish the information contained in ...
Subscribe to LegalLaw247.Com Newsletter
